Fast Forward - Neoadjuvant Cancer Immunotherapy

被引：11

作者：

Gajewski, Thomas F. ^{[1
,2
,3
]}

机构：

[1] Univ Chicago, Dept Pathol, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA

[2] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA

[3] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 378卷 / 21期

关键词：

PD-1; BLOCKADE;

D O I：

10.1056/NEJMe1803923

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immunotherapies that are based on blocking the axis of the programmed death 1 (PD-1) pathway are having a transformational effect in cancer medicine. To date, the Food and Drug Administration has approved PD-1 pathway inhibitors for 10 types of cancer, with continued clinical study under way. The therapeutic efficacy of these drugs relies on endogenous tumor-antigen-specific T cells that are functionally held in check by negative signaling through PD-1. Preclinical models and human correlative biomarker data indicate that efficacy depends on antitumor CD8+ T cells that are recruited into the tumor microenvironment and that are functionally restrained. Treatment with PD-1. Copyright © 2018 Massachusetts Medical Society.

引用

页码：2034 / 2035

页数：3

共 8 条

[1] IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J].

Ayers, Mark ;

Lunceford, Jared ;

Nebozhyn, Michael ;

Murphy, Erin ;

Loboda, Andrey ;

Kaufman, David R. ;

Albright, Andrew ;

Cheng, Jonathan D. ;

Kang, S. Peter ;

Shankaran, Veena ;

Piha-Paul, Sarina A. ;

Yearley, Jennifer ;

Seiwert, Tanguy Y. ;

Ribas, Antoni ;

McClanahan, Terrill K. .

JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) :2930-2940

[2] Neoadjuvant PD-1 Blockade in Resectable Lung Cancer [J].

Forde, P. M. ;

Chaft, J. E. ;

Smith, K. N. ;

Anagnostou, V. ;

Cottrell, T. R. ;

Hellmann, M. D. ;

Zahurak, M. ;

Yang, S. C. ;

Jones, D. R. ;

Broderick, S. ;

Battafarano, R. J. ;

Velez, M. J. ;

Rekhtman, N. ;

Olah, Z. ;

Naidoo, J. ;

Marrone, K. A. ;

Verde, F. ;

Guo, H. ;

Zhang, J. ;

Caushi, J. X. ;

Chan, H. Y. ;

Sidhom, J. -W. ;

Scharpf, R. B. ;

White, J. ;

Gabrielson, E. ;

Wang, H. ;

Rosner, G. L. ;

Rusch, V. ;

Wolchok, J. D. ;

Merghoub, T. ;

Taube, J. M. ;

Velculescu, V. E. ;

Topalian, S. L. ;

Brahmer, J. R. ;

Pardoll, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (21) :1976-1986

[3] Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease [J].

Liu, Jing ;

Blake, Stephen J. ;

Yong, Michelle C. R. ;

Harjunpaa, Heidi ;

Ngiow, Shin Foong ;

Takeda, Kazuyoshi ;

Young, Arabella ;

O'Donnell, Jake S. ;

Allen, Stacey ;

Smyth, Mark J. ;

Teng, Michele W. L. .

CANCER DISCOVERY, 2016, 6 (12) :1382-1399

[4] Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade [J].

McGranahan, Nicholas ;

Furness, Andrew J. S. ;

Rosenthal, Rachel ;

Ramskov, Sofie ;

Lyngaa, Rikke ;

Saini, Sunil Kumar ;

Jamal-Hanjani, Mariam ;

Wilson, Gareth A. ;

Birkbak, Nicolai J. ;

Hiley, Crispin T. ;

Watkins, Thomas B. K. ;

Shafi, Seema ;

Murugaesu, Nirupa ;

Mitter, Richard ;

Akarca, Ayse U. ;

Linares, Joseph ;

Marafioti, Teresa ;

Henry, Jake Y. ;

Van Allen, Eliezer M. ;

Miao, Diana ;

Schilling, Bastian ;

Schadendorf, Dirk ;

Garraway, Levi A. ;

Makarov, Vladimir ;

Rizvi, Naiyer A. ;

Snyder, Alexandra ;

Hellmann, Matthew D. ;

Merghoub, Taha ;

Wolchok, Jedd D. ;

Shukla, Sachet A. ;

Wu, Catherine J. ;

Peggs, Karl S. ;

Chan, Timothy A. ;

Hadrup, Sine R. ;

Quezada, Sergio A. ;

Swanton, Charles .

SCIENCE, 2016, 351 (6280) :1463-1469

[5] Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab [J].

Riaz, Nadeem ;

Havel, Jonathan J. ;

Makarov, Vladimir ;

Desrichard, Alexis ;

Urba, Walter J. ;

Sims, Jennifer S. ;

Hodi, F. Stephen ;

Martin-Algarra, Salvador ;

Mandal, Rajarsi ;

Sharfman, William H. ;

Bhatia, Shailender ;

Hwu, Wen-Jen ;

Gajewski, Thomas F. ;

Slingluff, Craig L., Jr. ;

Chowell, Diego ;

Kendall, Sviatoslav M. ;

Chang, Han ;

Shah, Rachna ;

Kuo, Fengshen ;

Morris, Luc G. T. ;

Sidhom, John-William ;

Schneck, Jonathan P. ;

Horak, Christine E. ;

Weinhold, Nils ;

Chan, Timothy A. .

CELL, 2017, 171 (04) :934-+

[6] Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells [J].

Spranger, Stefani ;

Spaapen, Robbert M. ;

Zha, Yuanyuan ;

Williams, Jason ;

Meng, Yuru ;

Ha, Thanh T. ;

Gajewski, Thomas F. .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (200)

[7] PD-1 blockade induces responses by inhibiting adaptive immune resistance [J].

Tumeh, Paul C. ;

Harview, Christina L. ;

Yearley, Jennifer H. ;

Shintaku, I. Peter ;

Taylor, Emma J. M. ;

Robert, Lidia ;

Chmielowski, Bartosz ;

Spasic, Marko ;

Henry, Gina ;

Ciobanu, Voicu ;

West, Alisha N. ;

Carmona, Manuel ;

Kivork, Christine ;

Seja, Elizabeth ;

Cherry, Grace ;

Gutierrez, Antonio J. ;

Grogan, Tristan R. ;

Mateus, Christine ;

Tomasic, Gorana ;

Glaspy, John A. ;

Emerson, Ryan O. ;

Robins, Harlan ;

Pierce, Robert H. ;

Elashoff, David A. ;

Robert, Caroline ;

Ribas, Antoni .

NATURE, 2014, 515 (7528) :568-+

[8] Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma [J].

Weber, J. ;

Mandala, M. ;

Del Vecchio, M. ;

Gogas, H. J. ;

Arance, A. M. ;

Cowey, C. L. ;

Dalle, S. ;

Schenker, M. ;

Chiarion-Sileni, V. ;

Marquez-Rodas, I. ;

Grob, J-J. ;

Butler, M. O. ;

Middleton, M. R. ;

Maio, M. ;

Atkinson, V. ;

Queirolo, P. ;

Gonzalez, R. ;

Kudchadkar, R. R. ;

Smylie, M. ;

Meyer, N. ;

Mortier, L. ;

Atkins, M. B. ;

Long, G. V. ;

Bhatia, S. ;

Lebbe, C. ;

Rutkowski, P. ;

Yokota, K. ;

Yamazaki, N. ;

Kim, T. M. ;

de Pril, V. ;

Sabater, J. ;

Qureshi, A. ;

Larkin, J. ;

Ascierto, P. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19) :1824-1835

← 1 →